Aberrant promoter CpG methylation and its translational applications in breast cancer

Chinese Journal of Cancer

Volumn 32, Issue 1, 2013, Pages 12-20

  Xiang, Ting Xiu ^a   Yuan, Ying ^a   Li, Li Li ^b,c   Wang, Zhao Hui ^b,c   Dan, Liang Ying ^a   Chen, Yan ^c   Ren, Guo Sheng ^a   Tao, Qian ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Breast cancer; CpG; Methylation; Tumor marker; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; AZACITIDINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIGALLOCATECHIN GALLATE; EPIRUBICIN; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; TRASTUZUMAB; TRICHOSTATIN A; TUMOR MARKER; VALPROIC ACID; ZEBULARINE;

ADVANCED CANCER; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CPG ISLAND; DIGITAL MAMMOGRAPHY; DNA METHYLATION; DRUG MECHANISM; DRUG TARGETING; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; HEREDITY; HUMAN; MALIGNANT MESOTHELIOMA; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRELEUKEMIA; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HUMANS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84872200942     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10344     Document Type: Review

References (129)

1. American cancer society's breast cancer resource. Availiable at: http://www.cancer.org.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011,61:69-90.
3. Radpour R, Barekati Z, Kohler C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One, 2011,6:e16080.
4. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet, 2007,8:286-298.
5. Singal R, Ginder GD. DNA methylation. Blood, 1999,93:4059-4070.
6. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene, 2002,21:5462-5482.
7. Polyak K. Breast cancer: origins and evolution. J Clin Invest, 2007,117:3155-3163.
8. Clarke R, Thompson EW, Leonessa F, et al. Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat, 1993,24:227-239.
9. Parrella P. Epigenetic signatures in breast cancer: clinical perspective. Breast Care (Basel), 2010,5:66-73.
10. Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res, 2009, 69:5194-5201.
11. Cui Y, Ying Y, van Hasselt A, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One, 2008,3:e2990.
12. Ai L, Tao Q, Zhong S, et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis, 2006,27: 1341-1348.
13. Xiang T, Li L, Fan Y, et al. PLCD1 is a functional tumor suppressor inducing G (2)/M arrest and frequently methylated in breast cancer. Cancer Biol Ther, 2010,10:520-527.
14. Shao L, Cui Y, Li H, et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res, 2007,13:5756-5762.
15. Low JS, Tao Q, Ng KM, et al. A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene, 2011,30:1923-1935.
16. Lee KY, Geng H, Ng KM, et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene, 2008, 27:5267-5276.
17. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol, 2001,19:924-930.
18. Kioulafa M, Balkouranidou I, Sotiropoulou G, et al. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer, 2009,125: 2887-2892.
19. Potapova A, Hoffman AM, Godwin AK, et al. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res, 2008,68: 998-1002.
20. Karray-Chouayekh S, Trifa F, Khabir A, et al. Clinical significance of epigenetic inactivation of hMLH1 and BRCA1 in Tunisian patients with invasive breast carcinoma. J Biomed Biotechnol, 2009,2009:369129.
21. Veeck J, Wild PJ, Fuchs T, et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer, 2009,9:217.
22. Tian K, Wang Y, Huang Y, et al. Methylation of WTH3, a possible drug resistant gene, inhibits p53 regulated expression. BMC Cancer, 2008,8:327.
23. Ko E, Park SE, Cho EY, et al. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Breast Cancer Res, 2010,12:R100.
24. Brooks J, Cairns P, Zeleniuch-Jacquotte A. Promoter methylation and the detection of breast cancer. Cancer Causes Control, 2009,20:1539-1550.
25. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-s pecific PCR. Lancet, 2001,357:1335-1336.
26. Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-s pecific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res, 2004,64:4442-4452.
27. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-s pecific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res, 2006,12:3306-3310.
28. Veeck J, Niederacher D, An H, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene, 2006,25:3479-3488.
29. Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat, 2006,100:169-176.
30. Yan PS, Perry MR, Laux DE, et al. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res, 2000,6:1432-1438.
31. Holm K, Hegardt C, Staaf J, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res, 2010,12:R36.
32. Widschwendter M, Menon U. Circulating methylated DNA: a new generation of tumor markers. Clin Cancer Res, 2006,12: 7205-7208.
33. Muller HM, Widschwendter A, Fiegl H, et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res, 2003,63:7641-7645.
34. Dulaimi E, Hillinck J, Ibanez de Caceres I, et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res, 2004,10:6189-6193.
35. Martinez-Galan J, Torres B, Del Moral R, et al. Quantitative detection of methylated ESR1 and 14-3-3-si gma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther, 2008,7:958-965.
36. Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta, 2009,404:100-104.
37. Suijkerbuijk KP, van der Wall E, van Diest PJ. Oxytocin: bringing magic into nipple aspiration. Ann Oncol, 2007,18: 1743-1744.
38. Sun Z, Asmann YW, Kalari KR, et al. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One, 2011,6:e17490.
39. Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst, 2006,98:1443-1444.
40. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol, 2007,25:4603-4609.
41. Samuels BL, Herndon JE, 2nd, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer, 1998,82:1578-1584.
42. Tao Q, Young LS, Woodman CB, et al. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci, 2006,11:2672-2713.
43. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov, 2005,4:275-276.
44. Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat, 2010,120:581-592.
45. Yan L, Nass SJ, Smith D, et al. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther, 2003,2:552-556.
46. Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res, 2009,15: 3177-3183.
47. Klisovic RB, Stock W, Cataland S, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res, 2008,14:2444-2449.
48. Brueckner B, Garcia Boy R, Siedlecki P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res, 2005,65:6305-6311.
49. Zheng YG, Wu J, Chen Z, et al. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev, 2008,28:645-687.
50. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet, 1999,21: 103-107.
51. Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res, 2001,61: 7025-7029.
52. Jang ER, Lim SJ, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene, 2004,23: 1724-1736.
53. Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res, 2005, 11: 6382-6389.
54. Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-re gulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther, 2003,2:971-984.
55. Hurtubise A, Momparler RL. Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs, 2004,15:161-167.
56. Li Y, Yuan YY, Meeran SM, et al. Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol Cancer, 2010,9:274.
57. Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One, 2010,5:e11457.
58. Ganesan A, Nolan L, Crabb SJ, et al. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets, 2009,9:963-981.
59. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol, 2007,25:1979-1985.
60. Vo QN, Kim WJ, Cvitanovic L, et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene, 2004,23:9432-9437.
61. David GL, Yegnasubramanian S, Kumar A, et al. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-A za-cytidine. Cancer Biol Ther, 2004,3:540-548.
62. Dejeux E, Ronneberg JA, Solvang H, et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer, 2010,9:68.
63. Virmani AK, Rathi A, Sathyanarayana UG, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res, 2001,7:1998-2004.
64. Jin Z, Tamura G, Tsuchiya T, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer, 2001,85:69-73.
65. Li Z, Chen B, Wu Y, et al. Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors. BMC Cancer, 2010,10:98.
66. Kuznetsova EB, Kekeeva TV, Larin SS, et al. Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J Carcinog, 2007,6:9.
67. Tapia T, Smalley SV, Kohen P, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics, 2008,3:157-163.
68. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst, 2000,92:564-569.
69. Si J, Yu X, Zhang Y, et al. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer, 2010,9:92.
70. Yang X, Karuturi RK, Sun F, et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One, 2009, 4: e5011.
71. Rivenbark AG, Livasy CA, Boyd CE, et al. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp Mol Pathol, 2007,83:188-197.
72. Ai L, Kim WJ, Kim TY, et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res, 2006,66:7899-7909.
73. Paredes J, Albergaria A, Oliveira JT, et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res, 2005,11:5869-5877.
74. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res, 2001, 61:4556-4560.
75. Loo WT, Jin L, Cheung MN, et al. Epigenetic change in E-cadherin and COX-2 to predict chronic periodontitis. J Transl Med, 2010,8:110.
76. Dietrich D, Krispin M, Dietrich J, et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. BMC Cancer, 2010,10:247.
77. Hill VK, Hesson LB, Dansranjavin T, et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer, 2010,9:51.
78. Evron E, Umbricht CB, Korz D, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res, 2001, 61: 2782-2787.
79. Van der Auwera I, Bovie C, Svensson C, et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer, 2010,10:97.
80. Suzuki H, Toyota M, Carraway H, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer, 2008,98:1147-1156.
81. Veeck J, Bektas N, Hartmann A, et al. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res, 2008,10:R82.
82. Seng TJ, Low JS, Li H, et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene, 2007,26:934-944.
83. Nass SJ, Herman JG, Gabrielson E, et al. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res, 2000,60:4346-4348.
84. Ottaviano YL, Issa JP, Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res, 1994,54:2552-2555.
85. Lapidus RG, Nass SJ, Butash KA, et al. Mapping of ER gene CpG island methylation-s pecific polymerase chain reaction. Cancer Res, 1998,58:2515-2519.
86. Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res, 1995,55:5195-5199.
87. Wiesmann F, Veeck J, Galm O, et al. Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer. Breast Cancer Res, 2009,11:R34.
88. Fu DY, Wang ZM, Wang BL, et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. Hum Pathol, 2010,41:48-58.
89. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer, 2005,116:407-414.
90. Akhoondi S, Lindstrom L, Widschwendter M, et al. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethy-lation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res, 2010,12:R105.
91. Wang W, Huper G, Guo Y, et al. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene, 2005,24:2705-2714.
92. Esteller M, Corn PG, Urena JM, et al. Inactivation of glutathione S-transferase P1 gene by promoter hyper-methylation in human neoplasia. Cancer Res, 1998,58:4515-4518.
93. Das PM, Thor AD, Edgerton SM, et al. Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene, 2010,29:5214-5219.
94. Wales MM, Biel MA, El Deiry W, et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med, 1995,1:570-577.
95. Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer, 2003,107:970-975.
96. Krop IE, Sgroi D, Porter DA, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A, 2001, 98:9796-9801.
97. Raman V, Martensen SA, Reisman D, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature, 2000,405:974-978.
98. Issa JP, Vertino PM, Boehm CD, et al. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A, 1996,93:11757-11762.
99. Brevet M, Fucks D, Chatelain D, et al. Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation. Pancreas, 2009,38:649-654.
100. Shah R, Smith P, Purdie C, et al. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br J Cancer, 2009,100:1687-1696.
101. Lapidus RG, Ferguson AT, Ottaviano YL, et al. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res, 1996,2: 805-810.
102. Keen JC, Garrett-Mayer E, Pettit C, et al. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther, 2004,3:1304-1312.
103. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/ p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res, 1995,55:4525-4530.
104. Suijkerbuijk KP, Fackler MJ, Sukumar S, et al. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol, 2008,19:1870-1874.
105. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet, 2001,10:3001-3007.
106. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res, 2001,61:3225-3229.
107. Lehmann U, Langer F, Feist H, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol, 2002,160:605-612.
108. Di Vinci A, Perdelli L, Banelli B, et al. p16 (INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer, 2005,114:414-421.
109. Garcia JM, Silva J, Pena C, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer, 2004,41:117-124.
110. Widschwendter M, Berger J, Hermann M, et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst, 2000,92:826-832.
111. Sirchia SM, Ren M, Pili R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res, 2002,62:2455-2461.
112. Du Y, Carling T, Fang W, et al. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res, 2001,61:8094-8099.
113. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res, 2001,61:3105-3109.
114. Yeo W, Wong WL, Wong N, et al. High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tu mourous tissue of breast cancer. Pathology, 2005,37:125-130.
115. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res, 2005,65:3497-3508.
116. Yang ZQ, Liu G, Bollig-Fischer A, et al. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers. Int J Cancer, 2009,125:1613-1621.
117. Dahl E, Veeck J, An H, et al. Epigenetic inactivation of the WNT antagonist SFRP1 in breast cancer. Verh Dtsch Ges Pathol, 2005,89:169-177.
118. Veeck J, Geisler C, Noetzel E, et al. Epigenetic inactivation of the secreted frizzled-re lated protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis, 2008,29:991-998.
119. Fu DY, Wang ZM, Li C, et al. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat, 2010,119: 601-612.
120. Xu XL, Wu LC, Du F, et al. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res, 2001,61:7943-7949.
121. Yuan Y, Mendez R, Sahin A, et al. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res, 2001,61:5558-5561.
122. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res, 1999,59:798-802.
123. Antill YC, Mitchell G, Johnson SA, et al. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev, 2010,19:265-274.
124. Conway KE, McConnell BB, Bowring CE, et al. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-in duced gene silencing in human breast cancers. Cancer Res, 2000,60:6236-6242.
125. Ai L, Kim WJ, Demircan B, et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis, 2008,29:510-518.
126. Hsu CC, Leu YW, Tseng MJ, et al. Functional characterization of Trip10 in cancer cell growth and survival. J Biomed Sci, 2011,18:12.
127. Li Z, Meng ZH, Chandrasekaran R, et al. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res, 2002,62:1939-1943.
128. Ferguson AT, Evron E, Umbricht CB, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A, 2000,97: 6049-6054.
129. Umbricht CB, Evron E, Gabrielson E, et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene, 2001,20:3348-3353.